This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shachaf, C. M. Articles by Felsher, D. W. Search for Related Content PubMed PubMed Citation Articles by Shachaf, C. M. Articles by Felsher, D. W. Related Collections Cellular Pathobiology Cellular Pathobiology: Proliferation, Senescence, and Death

Tumor Dormancy and MYC Inactivation: Pushing Cancer to the Brink of Normalcy

Division of Oncology, Departments of Medicine and Pathology Stanford University, Stanford, California

Requests for reprints: Dean W. Felsher, Division of Oncology, Departments of Medicine and Oncology, CCSR 1150, MC 5151 Stanford University, Stanford, CA, 94305. Phone: 650-498-5269; Fax: 650-725-1420; E-mail: dfelsher{at}stanford.edu.

Upon MYC inactivation, tumors variously undergo proliferative arrest, cellular differentiation, and apoptosis and in some cases, apparently permanently revoking tumorigenesis. In liver tumor cells, we recently showed that MYC inactivation uncovers stem cell properties and triggers differentiation, but in this case, their neoplastic properties are restorable by MYC reactivation. Thus, whereas oncogene inactivation can push cancer to the brink of normalcy, some cells retain the latent capacity to turn cancerous again, arguing that they may exist in a state of tumor dormancy.

This article has been cited by other articles:

				H. Jo, Y. Jia, K. K. Subramanian, H. Hattori, and H. R. Luo Cancer Cell-Derived Clusterin Modulates the Phosphatidylinositol 3'-Kinase-Akt Pathway through Attenuation of Insulin-Like Growth Factor 1 during Serum Deprivation Mol. Cell. Biol., July 1, 2008; 28(13): 4285 - 4299. [Abstract] [Full Text] [PDF]

				D. W. Felsher, I. B. Weinstein, and A. Joe Oncogene Addiction versus Oncogene Amnesia: Perhaps More than Just a Bad Habit? Cancer Res., May 1, 2008; 68(9): 3081 - 3086. [Abstract] [Full Text] [PDF]

				V. B. Sampson, N. H. Rong, J. Han, Q. Yang, V. Aris, P. Soteropoulos, N. J. Petrelli, S. P. Dunn, and L. J. Krueger MicroRNA Let-7a Down-regulates MYC and Reverts MYC-Induced Growth in Burkitt Lymphoma Cells Cancer Res., October 15, 2007; 67(20): 9762 - 9770. [Abstract] [Full Text] [PDF]

				A. Saudemont, A. Hamrouni, P. Marchetti, J. Liu, N. Jouy, D. Hetuin, F. Colucci, and B. Quesnel Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1 Cancer Res., May 1, 2007; 67(9): 4491 - 4498. [Abstract] [Full Text] [PDF]

				D. W. Felsher Validating Oncogenes as Therapeutic Targets Using Conditional Transgenic Models Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 27 - 36. [Full Text] [PDF]

				C. Morrison, M. Radmacher, N. Mohammed, D. Suster, H. Auer, S. Jones, J. Riggenbach, N. Kelbick, G. Bos, and J. Mayerson MYC Amplification and Polysomy 8 in Chondrosarcoma: Array Comparative Genomic Hybridization, Fluorescent In Situ Hybridization, and Association With Outcome J. Clin. Oncol., December 20, 2005; 23(36): 9369 - 9376. [Abstract] [Full Text] [PDF]